Pharmacologic management of epilepsy in the elderly

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)

Volumn 41, Issue 3, 2001, Pages 421-436

  Bourdet, Sharya Vaughan ^a   Gidal, Barry E ^b   Alldredge, Brian K ^c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ABSORPTION; AGED; DRUG INTERACTION; EPILEPSY; HUMAN; LIVER; METABOLISM; REVIEW; TISSUE DISTRIBUTION;

ABSORPTION; AGED; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; HUMANS; LIVER; TISSUE DISTRIBUTION;

EID: 0035345582     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1086-5802(16)31256-6     Document Type: Review

References (181)

1. United Nations Population Division. Revision of the World Population Estimates and Projections. Available at: www.undp.org/popin/wdtrends/pop1998/. Accessed March 12, 2001.
2. U.S. Bureau of the Census. Projections of the total resident population by 5-year age groups, and sex with special age categories: Middle Series, 2050–70. Available at: www.census.gov/population/projections/nation/summary/np-t3-.g.txt. Accessed March 12, 2001.
3. R.K. Verbeeck J.A. Cardinal S.M. Wallace Effect of age and sex on the plasma binding of acidic and basic drugs Eur J Clin Pharmacol. 27 1984 91 97
4. H.A. Wynne L.H. Cope E. Mutch The effect of age upon liver volume and apparent liver blood flow in healthy man Hepatology. 9 1989 297 301
5. D.J. Greenblatt E.M. Sellers R.I. Shader Drug disposition in old age N Engl J Med. 306 1982 1081 1088
6. L. Nolan K. O'Malley Prescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactions J Am Geriatr Soc 36 1988 142 149
7. T.E. Lackner J.C. Cloyd L.W. Thomas I.E. Leppik Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use Epilepsia. 39 1998 1083 1087
8. W.A. Hauser J.F. Annegers L.T. Kurland Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984 Epilepsia. 34 1993 453 468
9. R. Tallis G. Hall I. Craig A. Dean How common are epileptic seizures in old age? Age Ageing. 20 1991 442 448
10. J. Loiseau P. Loiseau B. Duche A survey of epileptic disorders in southwest France: seizures in elderly patients Ann Neurol. 27 1990 232 237
11. W.A. Hauser Seizure disorders: the changes with age Epilepsia 33 suppl 4 1992 S6 S14
12. A.B. Ettinger S. Shinnar New-onset seizures in an elderly hospitalized population Neurology. 43 1993 489 492
13. J. Reith H.S. Jorgensen H. Nakayama Seizures in acute stroke: predictors and prognostic significance The Copenhagen Stroke Study. Stroke. 28 1997 1585 1589
14. J. Burn M. Dennis J. Bamford P. Sandercock Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project Br Med J 315 7122 1997 1582 1587
15. M.F. Romanelli J.C. Morris K. Ashkin L.A. Coben Advanced Alzheimer's disease is a risk factor for late-onset seizures Arch Neural. 47 1990 847 850
16. D.C. Hesdorffer W.A. Hauser J.F. Annegers Dementia and adultonset unprovoked seizures Neurology. 46 1996 727 730
17. A.M. Dam A. Fuglsang-Frederiksen U. Svarre-Olsen M. Dam Late-onset epilepsy: etiologies, types of seizure, and value of clinical investigation, EEG, and computerized tomography scan Epilepsia. 26 1985 227 231
18. A. Holt-Seitz E.C. Wirrell M.B. Sundaram Seizures in the elderly: etiology and prognosis Can J Neurol Sci. 26 1999 110 114
19. A. Bender Effect of age on intestinal absorption: implications for drug absorption in the elderly J Am Geriatr Soc. 16 1968 1331 1339
20. M.A. Evans E.J. Triggs M. Cheung Gastric emptying rate in the elderly: implications for drug therapy J Am Geriatr Soc. 29 1981 201 205
21. G. Forbes J. Reina Adult lean body mass declines with age: some longitudinal observations Metabolism. 19 1970 653 663
22. N. Shock D. Watkin B. Yiengst Age differences in water content of the body as related to basal oxygen consumption in males J Gerantal. 18 1963 1 8
23. A.D. Bender A. Post J.P. Meir Plasma protein binding of drugs as a function of age in adult human subjects J Pharm Sci. 64 1975 1711 1713
24. B.T. Veering A.G.L. Burn J.H.M. Souverijn The effect of age an serum concentrations of albumin and α1-acid glycoprotein Br J Clin Pharmacol. 29 1990 201 206
25. S.A. Friedman A.E. Raizner H. Rosen Functional defects in the aging kidney Ann Intern Med. 76 1972 41 45
26. D.F. Davies N.W. Shock Age related changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males J Clin Invest. 29 1950 496 507
27. J.W. Rowe R. Andres J.D. Tobin The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study J Gerantal. 31 1976 155 183
28. R.D. Lindeman J. Tobin N.W. Shock Longitudinal studies on the rate of decline in renal function with age J Am Geriatr Soc. 33 1985 278 285
29. B. Bach J.M. Hansen J.P. Kampman Disposition of antipyrine and phenytoin correlated with age and liver volume in man Clin Pharmacakinet. 6 1981 389 396
30. E.A. Sotaniemi A.J. Arranto O. Pelkonen M. Pasanen Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions Clin Pharmacol Ther. 61 1997 331 339
31. T. Tateishi A. Fujimura T. Shiga Influence of aging on the oxidative and conjugative metabolism of propranolol Int J Clin Pharmacol Res 15 3 1995 95 101
32. D.J. Greenblatt R.I. Shader J.S. Harmatz Implications of altered drug disposition in the elderly: studies of benzodiazepines J Clin Pharmacol. 29 1989 866 872
33. P.J. Cook R. Flanagan I.M. James Diazepam tolerance: effect of age, regular sedation, and alcohol Br Med J 289 6441 1984 351 353
34. S. Albrecht H. Ihmsen W. Hering The effect of age on the pharmacokinetics and pharmacodynamics of midazolam Clin Pharmacol Ther. 65 1999 630 639
35. H. Cameron G. Macphee Anticonvulsant therapy in the elderly—a need for placebo controlled trials Epilepsy Res. 21 1995 149 157
36. J.M. Rho R. Sankar The pharmacologic basis of antiepileptic drug action Epilepsia. 40 1999 1471 1483
37. M.J. Painter L.M. Gaus Phenobarbital: clinical use R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 401 407
38. D.B. Smith J. DeToledo Primidone: clinical use R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 477 485
39. W.E. Dodson R.S. Rust Phenobarbital: absorption, distribution, and excretion R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 379 387
40. H. Kutt Phenobarbital: interactions with other drugs R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 389 399
41. M.J. Eadie C.M. Lander W.D. Hooper J.H. Tyrer Factors influencing plasma phenobarbitone levels in epileptic patients Br J Clin Pharmacol. 4 1977 541 547
42. C. Martines G. Gatti E. Sasso The disposition of primidone in elderly patients Br J Clin Pharmacol. 30 1990 607 611
43. J.A. Cramer R.H. Mattson Phenobarbital: toxicity R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 409 420
44. M. Dossing H. Pilsgaard B. Rasmussen H.E. Poulsen Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism Eur J Clin Pharmacol. 25 1983 215 222
45. I. Bernus R.G. Dickinson W.D. Hooper M.J. Eadie Inhibition of phenobarbitone N-glucosidation by valproate Br J Clin Pharmacol. 38 1994 411 416
46. B.J. Wilder Phenytoin: clinical use R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 339 343
47. T.R. Browne B. LeDuc Phenytoin: chemistry and biotransformation R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 283 300
48. D.M. Treiman D.M. Woodbury Phenytoin: absorption, distribution, and excretion R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 301 314
49. M. Bajpai L.K. Roskos D.D. Shen R.H. Levy Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite Drug Metab Dispas. 24 1996 1401 1403
50. G.D. Anderson C. Pak K.W. Doane Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia Ann Pharmacather. 31 1997 279 284
51. L.A. Bauer R.A. Bloudin Age and phenytoin kinetics in adult epileptics Clin Pharmacol Ther. 31 1982 301 304
52. J. Bruni Phenytoin: toxicity R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 345 350
53. R.P. Remmel M.H. Nelson A.K. Birnbaum Phenytoin hydroxylation kinetics and inhibition by SSRI antidepressants in elderly human liver microsomes Epilepsia 40 suppl 7 1999 16
54. R.H. Levy M. Bajpai Phenytoin: interactions with other drugs. Part 2: mechanistic aspects R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed 1995 Raven Press New York, NY 329 338
55. H. Kutt Phenytoin: interactions with other drugs. Part 1: clinical aspects R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed 1995 Raven Press New York, NY 315 328
56. P. Loiseau B. Duche Carbamazepine: clinical use R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed 1995 Raven Press New York, NY 555 586
57. B.M. Kerr K.E. Thummel C.J. Wurden Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation Biachem Pharmacol 47 1994 1969 1979
58. 1-acid glycoprotein concentration Eur J Clin Pharmacol. 31 1986 85 89
59. N. Hockings A. Pall J. Moody The effects of age on carbamazepine pharmacokinetics and adverse effects Br J Clin Pharmacol. 22 1986 725 728
60. J.C. Cloyd T.E. Lackner I.E. Leppik Antiepileptics in the elderly: pharmacoepidemiology and pharmacokinetics Arch Fam Med. 3 1994 589 598
61. M.L. Scheuer K. McCullough Carbamazepine clearance in the elderly [abstract] Neurolagy 45 suppl 4 1995 A360
62. G.L. Holmes Carbamazepine: toxicity R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 567 579
63. T. Van Amelsvoort R. Bakshi C.B. Devaux S. Schwabe Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review Epilepsia. 35 1994 181 188
64. R. Kalff M.A. Houtkopper J.W.A. Meyer Carbamazepine and serum sodium levels Epilepsia. 25 1984 390 397
65. M.B. Lahr Hyponatremia during carbamazepine therapy Clin Pharmacol Ther. 37 1985 693 698
66. G. Kenneback L. Bergfeldt H. Vallin Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system Am Heart J. 121 1991 1421 1428
67. F. Albani R. Riva A. Baruzzi Clarithromycin-<:arbamazepine interaction: a case report Epilepsia. 34 1993 161 162
68. B.A. Wroblewski W.D. Singer J. Whyte Carbamazepine–erythromycin interaction. Case studies and clinical significance JAMA 255 1986 1165 1167
69. F.H. Bahls J. Ozuna D.E. Ritchie Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin Neurolagy. 41 1991 740 742
70. S.R. Grimsley M.W. Jann J.G. Carter Increased carbamazepine plasma concentrations after fluoxetine coadministration Clin Pharmacol Ther. 50 1991 10 15
71. B.E. Gidal G.D. Anderson T.L. Seaton Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide Ther Drug Manit. 15 1993 405 409
72. G.D. Anderson A mechanistic approach to antiepileptic drug interactions Ann Pharmacather. 32 1998 554 582
73. B. Rambeck A. Salke-Treumann T. May H.E. Boenigk Valproic acid induced carbamazepine 10,1 1-epoxide toxicity in children and adolescents Eur Neurol. 30 1990 79 83
74. P. Glue C.R. Banfield J.L. Perhach Pharmacokinetic interactions with felbamate. In vitro–in vivo correlation Clin Pharmacokinet 33 1997 214 224
75. B.F.D. Bourgeois Valproate: clinical use R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 633 639
76. R.H. Levy D.D. Shen Valproate: absorption, distribution, and excretion R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 605 619
77. L.A. Bauer R. Davis A. Wilensky Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults Clin Pharmacol Ther. 37 1985 697 700
78. E. Perucca R. Grimaldi G. Gatti Pharmacokinetics of valproic acid in the elderly Br J Clin Pharmacol. 17 1984 665 669
79. B.E. Gidal M. Collins B.R. Beinlich Apparent valproic acid neurotoxicity in a hypoalbuminemic patient Ann Pharmacather. 27 1993 32 34
80. F.E. Dreifuss Valproate: toxicity R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 641 648
81. C. Armon C. Shin P. Miller Reversible parkinsonism and cognitive impairment with chronic valproate use Neurology. 47 1996 626 635
82. Depakote [package insert]. North Chicago, Ill: Abbott Laboratories; 2000.
83. R.D. Scheyer R.H. Mattson Valproate: interactions with other drugs R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 621 631
84. R. Canger A. Vignoli R. Bonardi L. Guidolin Felbamate in refractory partial epilepsy Epilepsy Res. 34 1999 43 48
85. E. Faught R.C. Sachdeo M.P. Remler Felbamate monotherapy for partial-onset seizures: an active-control trial Neurology. 43 1993 688 692
86. B. Bourgeois I.E. Leppik J.C. Sackellares Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures Neurology. 43 1993 693 696
87. D.W. Kaufman J.P. Kelly T. Anderson Evaluation of case reports of aplastic anemia among patients treated with felbamate Epilepsia. 38 1997 1265 1269
88. A.J. Wilensky P.N. Friel L.M. Ojemann Pharmacokinetics of W-554 (ADD 03055) in epileptic patients Epilepsia. 26 1985 602 606
89. A. Richens C.R. Banfiled M. Salfi Single and multiple dose pharmacokinetics of felbamate in the elderly Br J Clin Pharmacol. 44 1997 129 134
90. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5. Neurology. 1993;43:2292-2298.
91. A. Beydoun J. Fischer D.R. Labar Gabapentin monotherapy: II. A 26-week double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures Neuralogy 49 1997 746 752
92. D. Chadwick H. Anhut G. Murray Gabapentin monotherapy in patients with newly-diagnosed epilepsy: results of a double-blind, fixed-dose study comparing three dosages of gabapentin and openlabel carbamazepine [abstract] Epilepsia 38 suppl 3 1997 S34
93. B.E. Gidal J. DeCerce H.R. Bockbrader Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy Epilepsy Res. 31 1998 91 99
94. K.O. Vollmer D. Turck H.N. Bockbrader Summary of Neurontin (gabapentin) clinical pharmacokinetics Epilepsia 33 suppl 3 1992 S77
95. R.A. Blum T.J. Comstock D.A. Sica Pharmacokinetics of gabapentin in subjects with various degrees of renal function Clin Pharmacol Ther. 56 1994 154 159
96. R.A. Boyd D. Turck R.B. Abel Effects of age and gender on singledose pharmacokinetics of gabapentin Epilepsia. 40 1999 474 479
97. J.A. Busch H.N. Bockbrader E.J. Randinitis Lack of clinically significant drug interactions with Neurontin (gabapentin) [abstract] Epllepsia 34 suppl 2 1993 S158
98. Neurontin [package insert]. Morris Plains, NJ: Parke-Davis; 1998.
99. J.T. Gilman Lamotrigine: an antiepileptic agent for the treatment of partial seizures Ann Pharmacother. 29 1995 144 151
100. J. Messenheimer R.E. Ramsay L.J. Willmore Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial Epilepsia. 35 1994 113 121
101. M. Reunanen M. Dam A.W.C. Yuen A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy Epilepsy Res. 23 1996 149 155
102. T.J. Steiner C.I. Dellaportas L.J. Findley Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin Epilepsia. 40 1999 601 607
103. R.G. Beran S.F. Berkovic F.M. Dunagan Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy Epilepsia. 39 1998 1329 1333
104. A.F. Chen G.S. Land D.D. Breimer Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans Clin Pharmacol Ther. 42 1987 535 541
105. R. Wootton J. Soul-Lawton P.E. Rolan Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers Br J Clin Pharmacol. 43 1997 23 27
106. J.P. Fillastre A.M. Taburet A. Fialaire Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis Drugs Exp Clin Res. 19 1993 25 32
107. J. Posner T. Holdich P. Chrome Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers J Pharm Med. 1 1991 121 128
108. N.T. Rodgers-Neame B.V. Gallo B.A. Carr Treatment of seizures in elderly patients with Lamictal monotherapy: a pilot study Epilepsia 40 suppl 7 1999 S149
109. M.J. Brodie P.W. Overstall L. Giorgi The UK Lamotrigine Elderly Study Group Epilepsy Res. 37 1999 81 87
110. J. Posner H. Webster W.C. Yuen Investigation of the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes Br J c/in Pharmacol. 32 1991 658
111. T. Grasela Fiedler–Kelly J, Cox E, et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy J Clin Pharmacol 39 1999 373 384
112. G.D. Anderson Yau Mk B.E. Gidal Bidirectional interaction of valproate and lamotrigine in healthy subjects Clin Pharmacol Ther. 60 1996 145 156
113. M. Depot J.R. Powell J.A. Messenheimer Kinetic effects of multipl.e oral doses of acetaminophen on a single oral dose of lamotrigine Clin Pharmacol Ther 48 1990 346 355
114. R.P. Shank J.F. Gardocki J.L. Vaught Topiramate: preclinical evaluation of a structurally novel anticonvulsant Epilepsia. 35 1994 450 460
115. M. Privitera R. Fincham J. Penry Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800, and 1,000 mg daily dosages Neurology. 46 1996 1678 1683
116. E. Faught B.J. Wilder R.E. Ramsay Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400, and 600 mg daily dosages Neuralogy. 46 1996 1684 1690
117. R.A. Reife G.W. Pledger Topiramate as adjunctive therapy in. refractory partial epilepsy: pooled analysis of data from five double-blind, place-bo-controlled trials Epilepsia 38 suppl 1 1997 S31 S33
118. W.E. Rosenfeld R.C. Sachdeo R.E. Faught M. Privitera Long-term experience with topiramate as adjunctive therapy and as monotherapy In patients with partial onset seizures: retrospective survey of open-label treatment Epilepsia 38 suppl 1 1997 S34 S36
119. V. Biton G.D. Montouris F. Ritter A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures Neurology. 52 1999 1330 1337
120. B.E. Gidal G.L. Lensmeyer Therapeutic drug monitoring of topiramate: evaluation of the saturable distribution between erythrocytes and plasma in whole blood using an optimized HPLC method Ther Drug Monit. 21 1992 567 576
121. E. Perucca Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs Epilepsia 37 suppl 2 1996 S8 S13
122. W.N. Wu J.B. Heebner A.J. Streeter Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men [abstract] Pharm Res 11 1994 S336 (suppl)
123. L.G. Gisclon J.M. Riffitts D.A. Sica The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function Pharm Res 10 suppl 1993 S397
124. Topamax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 1999.
125. J. Christensen J.H. Poulsen M. Dam Effects of age, gender, body weight and dosing profile on steady state trough concentrations of topiramate Epilepsia 40 suppl 7 1999 S105
126. R. Martin R. Kuzniecky S. Ho Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults Neurology. 52 1999 321 327
127. A. Alpati E. Faught Side effect profile on two different starting doses of topiramate Epilepsia 40 suppl7 1999 S141
128. A.G. Wasserstein I. Rak A. Reife Nephrolithiasis during treatment with topiramate Epilepsia 36 suppl 3 1995 S153
129. R.H. Levy F. Bishop A.J. Streeter Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum [abstract] Epilepsia 36 suppl 4 1995 S47
130. B.F.D. Bourgeois Drug interaction profile of topiramate Epilepsia 35 suppl 2 1996 Sl4 S17
131. S. Liao M. Palmer Digoxin and topiramate drug interaction study in male volunteers Pharm Res 10 suppl 1993 S405
132. R. Kalviainen M.J. Brodie J. Duncan A double-blind, placebo-controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures Epilepsy Res. 30 1998 31 40
133. L.C. Lassen K. Sommerville H.B. Mengel Summary of five controlled trials with tiagabine as adjunctive treatment of patients with partial seizures [abstract] Epilepsia 36 suppl 3 1995 S148
134. A.J. Rowan B. Uthman P. Ahmann Safety and efficacy of three dose levels of tiagabine HCI versus placebo as adjunctive treatment for complex partial seizures [abstract] Epilepsia 35 suppl 8 1994 S54
135. S. Schachter V. Biton S. Boellner Safety and efficacy of tiagabine HCI monotherapy in the treatment of partial seizures: high dose versus low dose [abstract] Epilepsia 36 suppl 3 1995 S148
136. S. Schachter B. Wannamaker W. Cahill Dose-ranging study to determine the tolerability of tiagabine HCI administered as monotherapy [abstract] Epilepsia 36 suppl 3 1995 S148
137. L.E. Gustavson H.B. Mengel Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses Epilepsia. 36 1995 605 611
138. 14C]tiagabine by human hepatic microsomes [abstract] Epilepsia 36 suppl 3 1995 S159
139. A. Cato J.X. Qian L.E. Gustavson Pharmacokinetics and safety of tiagabine in subjects with various degrees of renal function [abstract] Epilepsia 36 suppl 3 1995 S159
140. A. Cato L.E. Gustavson J. Qian Effect of renal impairment on the pharmacokinetics and tolerability oftiagabine Epilepsia. 39 1998 43 47
141. A.H. Lau L.E. Gustavson R. Sperelakis Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function Epilepsia. 38 1997 445 451
142. S. Snel J.A. Jansen H.B. Mengel The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy J Clin Pharmacol. 37 1997 1015 1020
143. E.E. Samara L.E. Gustavson T. EI-Shourbagy Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy Epilepsia 39 1998 868 873
144. I.E. Leppik L. Gram R. Deaton K.W. Sommerville Safety of tiagabine: summary of 53 trials Epilepsy Res. 33 1999 235 246
145. M.S. Thomsen L. Groes H. Agerso T. Kruse Lack of pharmacokinetic interaction between tiagabine and erythromycin J Clin Pharmacol. 38 1998 1051 1056
146. H. Mengel J.A. Jansen K.W. Sommerville Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol Epilepsia 36 suppl 3 1995 S160
147. S. Snel J.A. Jansen P.C. Pedersen Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin Eur J Clin Pharmacol. 54 1998 355 357
148. Keppra [package insert]. Smyrna, Ga: UCB Pharma, Inc; 1999.
149. M. Bialer Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) Epilepsy Res. 34 1999 1 41
150. M.J. McLean M. Schmutz A.W. Wamil Oxcarbazepine: mechanisms of action Epilepsia 35 suppl 3 1994 S5 S9
151. S.C. Schachter B. Vazquez R.S. Fisher Oxcarbazepine: doubleblind, randomized, placebo-control, monotherapy trial for partial seizures Neurology. 52 1999 732 737
152. M. Dam R. Ekberg Y. Loyning A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy Epilepsy Res. 3 1989 70 76
153. W. Christe G. Kramer U. Vigonius A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy Epilepsy Res. 26 1997 451 460
154. P.A. Bill U. Vigonius H. Pohlmann A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy Epilepsy Res. 27 1997 195 204
155. M. Dam L.H. Ostergaard Other antiepileptic drugs: oxcarbazepine R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 987 995
156. P. Lloyd G. Flesch W. Dieterle Clinical pharmacology and pharmacokinetics of oxcarbazepine Epilepsia 35 suppl 3 1994 S10 S13
157. Trileptal [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2000.
158. P.N.M. van Heiningen M.D. Eve B. Oosterhuis The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine Clin Pharmacol Ther. 50 1991 410 419
159. R.C. Sachdeo A.G. Wasserstein J. D'Souza Oxcarbazepine (Trileptal) effect on serum sodium [abstract] Epilepsia 40 suppl 7 1999 S103
160. O.A. Nielsen A.C. Johannessen B. Bardrum Oxcarbazepine-induced hyponatremia, a cross-sectional study Epilepsy Res. 2 1988 269 271
161. G. Zaccara P.F. Gangemi L. Bendoni Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine Ther Drug Manit. 15 1993 39 42
162. G. Kramer B. Tettenborn G. Flesch Oxcarbazepine-verapamil drug interaction in healthy volunteers Epilepsia 32 suppl 1 1991 S70 S71
163. T. Keranen J. Jolkkonen P.K. Jensen Absence of interaction between oxcarbazepine and erythromycin Acta Neural Scand. 86 1992 120 123
164. T. Keranen J. Jolkkonen Klosterskov (Sameas)-Jensen P, Menge GP. Oxcarbazepine does not react with cimetidine in healthy volunteers Acta Neural Scand 85 1992 239 242
165. G. Kramer B. Tettenborn P. Klosterskov-Jensen Oxcarbazepine does not affect the anticoagulant activity of warfarin Epilepsia. 33 1992 1145 1148
166. A.J. Wilensky P.N. Friel L.M. Ojemann Zonisamide in epilepsy: a pilot study Epilepsia. 26 1985 212 220
167. E. Faught Review of U.S. clinical trials of zonisamide in treatment of refractory partial-onset seizures [abstract] Epilepsia 40 suppl 7 1999 S94
168. I.E. Leppik L.J. Willmore R.W. Homan Efficacy and safety of zonisamide: results of a multicenter study Epilepsy Res. 14 1993 165 173
169. D. Schmidt R. Jacob Loiseau p, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial Epilepsy Res 15 1993 67 73
170. Zonegran [package insert]. South San Francisco, Calif: Elan Pharmaceuticals, Inc; 2000.
171. T. Ito T. Yamaguchi H. Miyazaki Pharmacokinetic studies of AD-810, a new antiepileptic compound Arzneimittelforschung. 32 1982 1581 1586
172. G.M. Kochak J.G. Page R.A. Buchanan Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures J Clin Pharmacol. 38 1998 166 171
173. D. Bergen Incidence of adverse events is reduced with titrated dosing of Zonegran (zonisamide) for partial seizures in the United States Epilepsia 40 suppl 7 1999 94
174. M. Seino S. Naruto T. Ito H. Miyazaki Other antiepileptic drugs: zonisamide R.H. Levy R.H. Mattson B.S. Meldrum Antiepileptic Drugs 4th ed. 1995 Raven Press New York, NY 1011 1023
175. L.M. Ojemann R.A. Shastri A.J. Wilensky Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy Ther Drug Manit. 8 1986 293 296
176. J.J. Schentag F.M. Gengo J.H. Wilton Influence of phenobarbital, cimetidine, and renal disease on zonisamide kinetics [abstract] Pharm Res 4 suppl 1987 S79
177. B. Alldredge Central nervous system drugs: anticonvulsants P.O. Anderson J.E. Knoben W.G. Troutman Handbook of Clinical Drug Data 9th ed. 1999 Appleton & Lange Stamford, Conn 406 431
178. D.C. Hesdorffer G. Logroscino G. Cascino Incidence of status epilepticus in Rochester, Minnesota, 1965-1984 Neurology. 50 1998 735 741
179. R.J. DeLorenzo W.A. Hauser A.R. Towne A prospective, population-based epidemiologic study of status epilepticus in Richmond Virginia. Neurology. 46 1996 1029 1035
180. D.H. Lowenstein B.K. Alldredge Status epilepticus N Engl J Med. 338 1998 970 976
181. R.E. Cranford I.E. Leppik B. Patrick Intravenous phenytoin: clinical and pharmacokinetic aspects Neurology. 28 1978 874 880